Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IRADIMED CORP (IRMD)

Iradimed Q1 2026 revenue rises 13% to $22.0 million; EPS up 22% to $0.45

Positive Impact 3 of 5 earnings Written later

Iradimed reported first-quarter 2026 revenue of $22.0 million, up 13%, and record GAAP diluted EPS of $0.45, up 22%. The company reaffirmed its full-year 2026 guidance and declared a $0.20 per share quarterly dividend, but its second-quarter 2026 revenue guidance of $20.0 million to $21.0 million sits below the first-quarter result.

Key points

  • Q1 2026 revenue was $22.0 million, up from $19.5 million; net income was $5.8 million, or $0.45 per diluted share, versus $0.37 a year earlier
  • Full-year 2026 guidance reaffirmed: revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05
  • Q2 2026 guidance: revenue of $20.0 million to $21.0 million and GAAP diluted EPS of $0.40 to $0.44
  • Quarterly dividend of $0.20 per share, record date May 15, 2026, payable May 29, 2026

The filing

CompanyIRADIMED CORP (IRMD)
Form8-K, current report
Filed with the SECMay 1, 2026, 8:45 AM ET
Accession number0001628280-26-029125

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.